Plain-English translation of NCT05568680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study of SynKIR-110, a new type of cancer treatment made from your own immune cells that have been engineered in the laboratory to fight tumors. Researchers are testing whether this treatment is safe and whether it can help people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has come back or worsened. The treatment involves collecting your immune cells, modifying them to recognize and attack cancer cells, and then putting the modified cells back into your body.
People with these types of advanced cancers often have limited treatment options after standard therapies stop working. This medication is designed to harness your own immune system to target cancer cells in a new way, potentially offering hope to patients who need additional treatment choices.
You likely qualify if…
You likely don't qualify if…
Your participation will involve several phases over about 12 months. First, you will have screening visits to confirm you are eligible, including blood tests and a procedure to collect your immune cells. Then, you will receive chemotherapy to prepare your body, followed by a single infusion of the treatment cells through an IV. After that, you will have regular follow-up visits to monitor your health and how you respond to the treatment for up to 12 months, or longer if your cancer progresses.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States